Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr. Maisel Goes To Washington: CDRH Advisor, Critic Joins Senior Staff

This article was originally published in The Gray Sheet

Executive Summary

CDRH has hired a longtime FDA advisor and sometimes outspoken agency and industry critic to lead efforts to improve the way new science is incorporated into agency policies

You may also be interested in...

Senate Dems Argue That Device Safety Act Will Not Curb Innovation

Senate Democrats are challenging the notion that removing federal pre-emption protection for PMA-approved devices, solidified last year by the Supreme Court, will stifle innovation

Heart Rhythm Experts Release New Pacer/ICD Lead Management Guidelines

New recommendations from leading heart experts call on physicians, device manufacturers and FDA to do a better job monitoring and managing the safety of pacemaker and implantable defibrillator leads

A Leading Question: When Is Human Testing Needed For ICD Approval?

Debate is surfacing in the medical and regulatory community over when clinical data is needed to approve new implantable cardioverter defibrillator technology

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts